Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

878.24
-18.7600-2.09%
Post-market: 875.00-3.2400-0.37%19:59 EDT
Volume:2.74M
Turnover:2.43B
Market Cap:830.27B
PE:38.27
High:900.83
Open:896.00
Low:877.11
Close:897.00
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.95
T/O Rate:0.29%
Dividend:6.00
Dividend Rate:0.68%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:31.29
PE(LYR):38.27

Loading ...

Lilly's Retevmo (Selpercatinib) Delivers Substantial Event-Free Survival Benefit as an Adjuvant Therapy in Early-Stage Ret Fusion-Positive Lung Cancer

THOMSON REUTERS
·
Feb 16

Eli Lilly - Overall Survival Results Trended in Favor of Selpercatinib, but Were Immature at Time of This Analysis With Few Events Observed

THOMSON REUTERS
·
Feb 16

Soros Fund Management Llc Reports Share Stake of 22,334 Shares in Eli Lilly & Co - SEC Filing

THOMSON REUTERS
·
Feb 14

Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia

TIPRANKS
·
Feb 14

Roche’s New Breast Cancer Trial Pits Its Pipeline Against Eli Lilly’s Standard: What It Means for RHHBY

TIPRANKS
·
Feb 14

Eli Lilly Prepares for Oral Weight-Loss Drug Market, Building Stockpiles Ahead of FDA Decision

Stock News
·
Feb 13

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 13

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Reuters
·
Feb 13

Eli Lilly: Expect Medicare Beneficiaries Will Have Access to Discounted Lilly Obesity Medicines by July 1, 2026

THOMSON REUTERS
·
Feb 13

Eli Lilly: Pre-Launch Inventories Capitalized as of Dec 31, 2025 Were $1.5 Bln, Primarily Related to Orforglipron- SEC Filing

THOMSON REUTERS
·
Feb 13

Eli Lilly posts FY 2025 net income of USD 20.64 billion, up nearly double

Reuters
·
Feb 13

Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings

TIPRANKS
·
Feb 13

More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds

Reuters
·
Feb 12

CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating

MT Newswires Live
·
Feb 11

Eli Lilly's Intestinal Disease Treatment Mirikizumab Receives Approval in China

Stock News
·
Feb 11

Eli Lilly: Mirikizumab Approved in China for Treatment of Moderate-to-Severe Crohn's Disease and Ulcerative Colitis - Co Statement

THOMSON REUTERS
·
Feb 11

Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares

TIPRANKS
·
Feb 11

Eli Lilly Expands Genetic Medicines Pipeline And Valuation Case With New Deals

Simply Wall St.
·
Feb 11

Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

Dow Jones
·
Feb 11

Eli Lilly upgraded to Buy from Hold at Freedom Capital

TIPRANKS
·
Feb 11